Skip to main content

Home/ Cancer/ Group items tagged oncology

Rss Feed Group items tagged

Matti Narkia

American Society of Clinical Oncology - ASCO - 0 views

  •  
    The American Society of Clinical Oncology (ASCO) is a non-profit organization, founded in 1964, with overarching goals of improving cancer care and prevention and ensuring that all patients with cancer receive care of the highest quality. More than 25,000 oncology practitioners belong to ASCO, representing all oncology disciplines (medical, radiation, and surgical oncology) and subspecialties. Members include physicians and health-care professionals participating in approved oncology training programs, oncology nurses, and other practitioners with a predominant interest in oncology.
medicoexperts

How does doctor decide Lung cancer treatment - 0 views

  •  
    In this video, Dr. Ramakant Deshpande explaining How does doctor decide Lung cancer treatment for different stages of Lung cancer. Lung cancer and its adversities can be lethal, if remains undiagnosed or left untreated. A multidisciplinary approach can successfully eliminate the cancer from lungs and patient may resume normal life after recovery, says Dr. Ramakant Dehspande, Chief of Thoracic Surgical Oncology, Asian Institute of Oncology. Lung cancer There are different sizes and stages of lung cancer, which are treated differently. Broadly, specialists categorize various types of lung cancer into two basic forms Non-small cell lung cancer and small cell lung cancer. The staging of lung cancer helps in deciding the severity of the disease, course of treatment, and chances of survival. Detection of cancer at an early stage increases the chances of successful treatment and full recovery of the patient. A small legion located in one area is known as the first stage; a little larger tumor is called stage 2; spread within the lungs is called stage 3, and if it spread to other parts then termed as stage 4. Doctor Profile: Dr. Ramakant Deshpande MS; FICS; FAIS; DHA having experience of 31+ years and is a Chief of Thoracic Surgical Oncology, Asian Institute of Oncology. - Padmashree award by the President of India in 2014 - Lifetime Achievement Award at the Indian National Critical Care Society Annual Meet at Jaipur 2014 - Lifetime Achievement Award by Zee Maaza TV in 2019 - Senior of Robotic surgery at the Asian Cancer Institute - Established the Minimally Invasive method of Thoracoscopy - President of the Indian Society of Oncology - Director - Asian Cancer Institute - Ex Tata Memorial Doctor This video is under the "My Health My Right" Initiative of MedicoExperts - A Global Virtual Hospital. For Inquiry Call or WhatsApp us at +919769516280 #lungcancertreatment​ #MyHealthMyRight​ #lungcancer​ #lungcancerstages​ #MedicoExperts​ #lungcancertreatmen
medicoexperts

6 Myths and Facts of Lung Cancer by Dr. Ramakant Deshpande, Padmashree award by Preside... - 0 views

  •  
    In this video Dr. Ramakant Deshpande explaining the 6 Myths and facts of Lung cancer. Dr. Ramakant Deshpande MS; FICS; FAIS; DHA having experience of 31+ years and is a Chief of Thoracic Surgical Oncology, Asian Institute of Oncology. - Padmashree award by the President of India in 2014 - Lifetime Achievement Award at the Indian National Critical Care Society Annual Meet at Jaipur 2014 - Lifetime Achievement Award by Zee Maaza TV in 2019 - Senior of Robotic surgery at the Asian Cancer Institute - Established the Minimally Invasive method of Thoracoscopy - President of the Indian Society of Oncology - Director - Asian Cancer Institute - Ex Tata Memorial Doctor This video is under the "My Health My Right" Initiative of MedicoExperts - A Global Virtual Hospital. For inquiry Call/WhatsApp us at +91 9769516280 #Lungcancer​ #MyHealthMyRight​ #lunghealth​ #lungtreatment​ #lungcancermyths​ #lungcancerfacts​ #MedicoExperts​ #DrRamakantDeshpande​ #oncology​ #cancer
Matti Narkia

Integrative Oncology: Donald Abrams and Andrew Weil - Oxford University Press - 0 views

  •  
    Integrative Oncology Donald Abrams and Andrew Weil SBN13: 9780195309447 ISBN10: 0195309448 Hardback, 624 pages Nov 2008, In Stock
Matti Narkia

Phase I trial of Seneca Valley Virus (NTX-010), a newly discovered systemically deliver... - 0 views

  •  
    Phase I trial of Seneca Valley Virus (NTX-010), a newly discovered systemically deliverable oncolytic picornavirus, in patients with solid tumors with neuroendocrine features. C. M. Rudin, D. Lansey, K. D. Burroughs, L. M. Hales, J. R. Neefe, P. S. Reddy and P. L. Hallenbeck Johns Hopkins Univ, Baltimore, MD; Neotropix, Inc., Malvern, PA. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 25, No 18S (June 20 Supplement), 2007: 18014 © 2007 American Society of Clinical Oncology. Conclusions: NTX-010 is a novel first-in-class anticancer virus with selective tropism for tumors with neuroendocrine features. This is the first anticancer virus given intravenously with documented selective intratumoral infection and replication. Administration was well tolerated. Safety data and viral kinetics will be presented.
medicoexperts

Doctors who cure Cancer | Medical Oncology - 0 views

  •  
    India's Top most Doctors of cancer treatment are associated with MedicoExperts and are available for face to face video conferencing. View Doctors Profile.
Matti Narkia

Mistletoe, a new branch of cancer treatment | Mail Online - 1 views

  •  
    "For years, it's been the perfect excuse for secret admirers to steal a kiss with the object of their desire. But research suggests mistletoe could do much more than just ignite Christmas passions. Scientists have found an extract of the plant could help to fight bowel cancer, which affects 37,500 a year in the UK. Patients who had the mistletoe treatment regularly injected into their blood had fewer side-effects from toxic chemotherapy and radiotherapy and survived longer than those who did not. The extract is thought to help the body's immune system fight tumours and speed up the disposal of toxic 'debris' left by chemotherapy. Researchers led by Professor Kurt Zanker from the German Institute of Immunology and Experimental Oncology, concluded: 'The results suggest convincing evidence that there is a significant benefit from treatment with mistletoe extract.' The scientists treated 429 cancer patients with the mistletoe jab and compared them with 375 receiving conventional care. The results, published in the journal of The Society For Integrative Oncology, showed only 19 per cent of those in the mistletoe group suffered side-effects from toxic treatments, compared to 48 per cent in the other group. They were also 32 per cent more likely to still be alive five years after starting therapy."
Tom Fields

Hematology and Oncologic Health Care - 0 views

  •  
    Diverse online repository of hematology and oncologic health care innovation profiles and tools.
Matti Narkia

A Novel Anti-angiogenesis Strategy for the Treatment of Head and Neck Cancer - News Arc... - 0 views

  •  
    A Novel Anti-angiogenesis Strategy for the Treatment of Head and Neck Cancer - News Archive: Michigan Oncology Journal Summer 01
Matti Narkia

Head and Neck Cancer Summary from 2006 ASCO Annual Meeting - 0 views

  •  
    American Society of Clinical Oncology Meeting 2006.
Matti Narkia

Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival Compared to Chemoth... - 0 views

  •  
    BSD Medical Corp. (Amex: BSM ) announced today that the results of a 340 patient randomized Phase III clinical trial testing the benefit of adding hyperthermia therapy to chemotherapy were presented at the annual American Society of Clinical Oncology (ASC
Tonny Johnson

Diagnostic and prognostic cancer biomarker database - 1 views

  •  
    A comprehensive diagnostic and prognostic cancer (oncology) biomarker database with cancer companion diagnostics biomarker pathway maps, which contain protein-protein interactions networks of cancer drug efficacy/response/predictive biomarkers. This database contains discovery, pre-clinical and clinical cancer biomarkers that were identified or validated using patient samples. The biomarkers include blood based cancer biomarkers, tumor biomarkers, urinary cancer biomarkers, fecal cancer biomarkers, saliva cancer biomarkers, breath cancer biomarkers etc. Patient/sample details, experimental results/observations, biological and molecular functional analysis, biological process analysis, protein-protein interaction networks of each biomarker are included in this database.Link (preview is available): http://www.sciclips.com/sciclips/diagnostic-prognostic-cancer-biomarker-main.do
Matti Narkia

MedWire News - Oncology - Serum 25(OH)D levels linked to prostate cancer prognosis - 0 views

  • The researchers conclude: “This study shows a strong association between 25(OH)D levels and cause-specific mortality in patients with prostate cancer. The strength of the association indicates that prostate cancer patients can benefit from increasing the level of serum 25(OH)D if it is below 50 nmol/l.”
  •  
    MedWire News: Serum levels of 25-hydroxy vitamin D (25(OH)D) play a role in prostate cancer disease progression and are a potential prognostic indicator, Norwegian study findings suggest.
Matti Narkia

Extra Virgin Olive Oil May Help To Combat Breast Cancer - 0 views

  •  
    ScienceDaily (Feb. 10, 2009) - UGR News Researchers of the Catalonian Institute of Oncology (Spain) and the University of Granada (Spain) have discovered that extra virgin olive oil may help to combat breast cancer, according to a paper published in a recent issue of 'BMC Cancer'. The scientists have confirmed the bioactivity of polyphenols (this is, natural antioxidants) present in olive oil in breast cancer cell lines.
Matti Narkia

MedWire News - Oncology - Vitamin D induces potential breast-tumor suppressor - 0 views

  •  
    MedWire News: Calcitriol, the active form of vitamin D, has been found to induce the tumor-suppressing protein CCAAT enhancer-binding protein (C/EBP)α, which can inhibit the growth of breast cancer cells, researchers report.
Matti Narkia

Newswise Medical News | Study on Role of Antioxidants in Reducing Chemotherapy Toxicity... - 0 views

  •  
    A new study showing a reduction in the toxic side effects of ROS-generating chemotherapies with concurrent antioxidant supplementation will be presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) that takes place June 1-5 at McCormick Place in Chicago. According to the study's authors, mitigating chemotherapy toxicity by supplementing with antioxidants may improve survival rates and tumor response by helping patients complete their prescribed treatment cycles.
Matti Narkia

Dichloroacetate (DCA) Promising for Endometrial Cancer - Cancer Treatments / Therapy R... - 0 views

  •  
    Dichloroacetate (DCA), a drug that has been used for many years in patients with metabolic disorders, has recently been gaining attention for its cancer-fighting capabilities. Studies in the lab have already shown its potential against lung, breast and glioblastoma cancer cells. Now a new study in the journal Gynecoogic Oncology finds that DCA might also be a promising therapy for endometrial cancer.
Matti Narkia

Oncology Journals - Guide to Internet Resources for Cancer - 0 views

  •  
    Cancer Related Medical Journals
Matti Narkia

Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head and Neck Cancer... - 0 views

  •  
    Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head and Neck Cancer. Corrected Proof, 7 August 2007 Leena Kankaanranta, Tiina Seppälä, Hanna Koivunoro, Kauko Saarilahti, Timo Atula, Juhani Collan, Eero Salli, Mika Kortesniemi, Jouni
1 - 20 of 60 Next › Last »
Showing 20 items per page